Terms: = Ovarian cancer AND CRTC1, Q6UUV9, 23373, ENSG00000105662, KIAA0616, TORC1, MECT1, WAMTP1, FLJ14027
3 results:
1. Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE).
de la Rosa CN; Krell J; Day E; Clarke A; Reddi M; Webber L; Fiorentino F
Trials; 2022 Jan; 23(1):13. PubMed ID: 34986897
[TBL] [Abstract] [Full Text] [Related]
2. Vistusertib (dual m-torc1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.
Basu B; Krebs MG; Sundar R; Wilson RH; Spicer J; Jones R; Brada M; Talbot DC; Steele N; Ingles Garces AH; Brugger W; Harrington EA; Evans J; Hall E; Tovey H; de Oliveira FM; Carreira S; Swales K; Ruddle R; Raynaud FI; Purchase B; Dawes JC; Parmar M; Turner AJ; Tunariu N; Banerjee S; de Bono JS; Banerji U
Ann Oncol; 2018 Sep; 29(9):1918-1925. PubMed ID: 30016392
[TBL] [Abstract] [Full Text] [Related]
3. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.
Raynaud FI; Eccles S; Clarke PA; Hayes A; Nutley B; Alix S; Henley A; Di-Stefano F; Ahmad Z; Guillard S; Bjerke LM; Kelland L; Valenti M; Patterson L; Gowan S; de Haven Brandon A; Hayakawa M; Kaizawa H; Koizumi T; Ohishi T; Patel S; Saghir N; Parker P; Waterfield M; Workman P
Cancer Res; 2007 Jun; 67(12):5840-50. PubMed ID: 17575152
[TBL] [Abstract] [Full Text] [Related]
